An area under the concentration–time curve threshold as a predictor of efficacy and nephrotoxicity for individualizing polymyxin B dosing in patients with carbapenem-resistant gram-negative bacteria

Jing Yang1,2,3, Shaohua Liu4, Jingli Lu1,2,3, Tongwen Sun4, Peile Wang1,2,3* and Xiaojian Zhang1,2,3*

Abstract

Background: Evidence supports therapeutic drug monitoring of polymyxin B, but clinical data for establishing an area under the concentration–time curve across 24 h at steady state (AUCss,24 h) threshold are still limited. This study aimed to examine exposure–response/toxicity relationship for polymyxin B to establish an AUCss,24 h threshold in a real-world cohort of patients.

Methods: Using a validated Bayesian approach to estimate AUCss,24 h from two samples, AUCss,24 h threshold that impacted the risk of polymyxin B-related nephrotoxicity and clinical response were derived by classification and regression tree (CART) analysis and validated by Cox regression analysis and logical regression analysis.

Results: A total of 393 patients were included; acute kidney injury (AKI) was 29.0%, clinical response was 63.4%, and 30-day all-cause mortality was 35.4%. AUCss,24 h thresholds for AKI of > 99.4 mg h/L and clinical response of > 45.7 mg h/L were derived by CART analysis. Cox and logical regression analyses showed that AUCss,24 h of > 100 mg h/L was a significant predictor of AKI (HR 16.29, 95% CI 8.16–30.25, \(P < 0.001\)) and AUCss,24 h of \(\geq 50\) mg h/L (OR 4.39, 95% CI 2.56–7.47, \(P < 0.001\)) was independently associated with clinical response. However, these exposures were not associated with mortality. In addition, the correlation between trough concentration (1.2–2.8 mg/L) with outcomes was similar to AUCss,24 h.

Conclusions: For critically ill patients, AUCss,24 h threshold of 50–100 mg h/L was associated with decreased nephrotoxicity while assuring clinical efficacy. Therapeutic drug monitoring is recommended for individualizing polymyxin B dosing.

Keywords: Polymyxin B, AUCss,24 h threshold, Nephrotoxicity, Efficacy, Therapeutic drug monitoring

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background

Polymyxins (i.e. colistin and polymyxin B) are old antibiotics that have been reintroduced in clinical practice because of the increasing incidence rate of carbapenem-resistant gram-negative bacteria (CR-GNB)
infections [1, 2]. However, nephrotoxicity is the most common adverse effect of polymyxins, with rates of acute kidney injury (AKI) ranging widely from 20 to 60% [3].

Pharmacokinetics (PK)/pharmacodynamics (PD) theory can effectively promote the rational use of antibiotics [4]. As an agent with wide inter-individual variability in PK and a narrow therapeutic index, polymyxin B is an ideal candidate for therapeutic drug monitoring (TDM) [5, 6]. An area under the concentration–time curve across 24 h at steady state (AUC\textsubscript{ss,24 h}) of 50–100 mg h/L is recommended for the treatment of CR-GNB with minimum inhibitory concentration (MIC) values of ≤2 mg/L, focusing on Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacteriaceae [7, 8]. However, it should be pointed out that the upper and lower bound of this therapeutic window was derived from a pharmacometrics meta-analysis of polymyxin B nephrotoxicity data and murine thigh infection PK/PD studies [9, 10]. Therefore, it is necessary to re-evaluate whether this threshold applies to critically ill patients.

Several studies have analyzed predictors for nephrotoxicity/efficacy and population PK of polymyxin B and reported dose as an independent predictor of AKI. Once daily dose is associated with AKI, it is expected that polymyxin B concentrations also be associated with AKI. However, a direct correlation between polymyxin B exposure and response/toxicity has not been well demonstrated [11–15]. Previously, we found that AUC\textsubscript{ss,24 h} of >100 mg h/L was a good predictor of the probability of nephrotoxicity (\( P = 0.001 \)) [16]. Ye et al. found that the therapeutic target of AUC\textsubscript{ss,24 h} (odds ratio [OR]= 13.15, \( P = 0.015 \)) was independently associated with favorable clinical outcomes of polymyxin B treatment [17]. Some studies reported that maintaining a trough concentration (\( C_{\text{th}} \) or \( C_{\text{min}} \)) of polymyxin B below 3.13 mg/L or peak concentration (\( C_{\text{max}} \)) of polymyxin B1 below 5.23 mg/L might help reduce the incidence of polymyxin B-related nephrotoxicity [18, 19]. After all, \( C_{\text{th}} \) is usually an appropriate choice for antibiotics with AUC/MIC as PK/PD index, such as linezolid, amikacin, and voriconazole [20]. However, considering the small sample size, further research is needed to validate the exposure target extensively.

The primary objective of this study was to validate an AUC\textsubscript{ss,24h} threshold of polymyxin B for predicting nephrotoxicity and efficacy in patients with CR-GNB infections. We also compared the effectiveness of AUC\textsubscript{ss,24h} and \( C_{\text{th}} \). In addition, risk factors for AKI, clinical efficacy, and mortality were evaluated.

**Methods**

**Patient enrollment and data collection**

This retrospective observational study was performed at the first affiliated hospital of Zhengzhou University. From April 2018 to March 2022, all patients (≥18 years) were included if they had received intravenous polymyxin B (sulfate; polymyxin B injection, Shanghai First Biochemical Pharmaceutical Co., Ltd., China) for the treatment of CR-GNB infections and had TDM. The susceptibility to carbapenems of the causative GNB was determined according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Enterobacteriaceae with MIC ≥4 mg/L and \( P. \ aeruginosa \) and Acinetobacter spp. with MIC ≥8 mg/L were considered resistant to carbapenem [21]. The EUCAST breakpoints of polymyxin B for the above bacterial strains were 2 mg/L or lower for susceptible and >2 mg/L for resistant [8]. Polymyxin-sensitive bacteria were performed using a VITEK® 2 COMPACT automated system (bioMérieux, Marcy-l’Étoile, France) with VITEK cards (0.5–16 mg/L for polymyxin). Exclusion criteria were (i) less than 18 years of age; (ii) received polymyxin B administration less than 96 h; (iii) received renal replacement therapy prior to polymyxin B therapy; (iv) had no pathogenic microorganism result; and (v) had wrong blood drawing time. This study was approved by the Ethics Committees of the First Affiliated Hospital of Zhengzhou University (2020-KY-0318) and waived informed consent given the retrospective nature.

Data were extracted from electronic medical records, including demographics, comorbidities, medication therapy, physiological parameters, and laboratory values on the day of polymyxin B initiation. In addition, severity of illness was quantified using the Acute Physiology and Chronic Health Enquiry (APACHE II) score and the Sequential Organ Failure Assessment (SOFA) score using the worst physiological parameters within 24 h before polymyxin B initiation [22, 23]. Diagnoses of infection site were based on clinical features and positive culture of CR-GNB in sterile localized, and the absence of any bacterial pollution or colonization by two physicians.

**Polymyxin B administration and concentration determination**

Polymyxin B package insert recommended doses of 1.5–3.0 mg/kg/day in two divided administrations. Therapy management was at the discretion of physicians, including dosage, infusion time, administration period, adjustment treatment, and concomitant antibiotics. Concomitant antibiotics referred to the use of other antibiotics with different mechanisms against pathogenic microorganisms to improve efficacy during
polymyxin B treatment. The type and treatment course of concomitant antibiotics were based on pathogen susceptibility results, clinical features, and Chinese consensus statements [24], and only that administered for at least 72 h during polymyxin B treatment were recorded. Moreover, the following medications or medication classes were considered potential nephrotoxic drugs: vancomycin (≥ 1.0 mg/day), aminoglycoside, amphotericin B, furosemide (≥ 20 mg/day), vasoactive drugs, and immunosuppressant, which should be concomitantly used at any time during polymyxin B therapy for at least 72 h.

Polymyxin B plasma concentrations were obtained as part of our hospital’s routine clinical practice of TDM. TDM was assessed first on day 4 and then repeated 48 h after dose adjustment. Dose adjustment was determined by physicians based on clinical features, MIC results, and the levels. Only the last TDM results were included in the study. For TDM, two blood samples were collected immediately before the infusion (C₀h) and 2 h after the beginning of infusion (C₂h). Blood samples were immediately centrifuged at 3500 × g for 10 min. The supernatant was collected and stored at −80 °C before analysis within one week.

The plasma concentrations of polymyxin B were determined using a validated ultra-performance liquid chromatography-tandem mass spectrometry previously published in our laboratory [25]. Briefly, the assay was linear over 0.2–10.0 µg/mL for polymyxin B1 and 0.05–2.5 µg/mL for polymyxin B2. The relative standard deviation (% RSD) of intra- and inter-batch assay ranged from 0 to 13.9% for quality control samples, and their corresponding accuracy (% relative error) ranged from −11.6 to 11.1%. Since polymyxin B1 and B2 had similar structures, molecular weight (Mol.), pharmacological activities, and PK characteristics, the concentration (Conc.) of polymyxin B was derived by the equation as Conc_{polymyxin B} = \frac{\text{Conc (polymyxin B1)}}{\text{Mol (polymyxin B1)}} + \frac{\text{Conc (polymyxin B2)}}{\text{Mol (polymyxin B2)}} × \text{Mol}_{avg (polymyxin B)}

For each patient, AUC_{ss,24h} was estimated using the Bayesian priors from our previously published population PK model using Phoenix® NLME software (v8.3, Pharsight, Mountain View, CA, USA) [26]. In short, the mean parameter vector and the variance–covariance matrix from a previously published two-compartment population PK model were used as the Bayesian prior, then to estimate the Bayesian conditional posterior PK parameters for each patient using the dosing, concentrations, and creatinine clearance (CrCl) values. Based on Bayesian conditional posterior PK parameters, the AUC_{ss,24h} were estimated. This approach had been validated to assess AUC values with high precision and low bias using C₀h and C₂h only [26]. CrCl was estimated according to the Cockcroft–Gault formula [27].

Endpoints

The primary endpoint was the occurrence of AKI, which was defined as a serum creatinine increase of 0.3 mg/L (26.5 µmol/L) and 50% from baseline on two consecutive measurements during polymyxin B treatment. Further classification was based on the Kidney Disease Improving Global Outcomes (KDIGO) criteria [28].

Secondary endpoints were clinical efficiency and 30-day all-cause mortality. Clinical response was considered at the end of treatment by two physicians: disappearance or improvement of clinical symptoms (body temperature < 38.0 °C), radiological resolution of signs of infection, and improved biochemistry indicators of infection (a ≥ 30% decrease in the total peripheral white blood cells count or C-reactive protein level). Patients who did not meet all above criteria were classified as clinical failure. Thirty-day mortality was recorded from the start of polymyxin B treatment.

Statistical analysis

Statistical analyses were performed using the Statistical Package for the Social Sciences version 26.0 (SPSS Inc., Chicago, IL, USA). Data were expressed as median with interquartile range (IQR) for continuous variables and percentages/frequency (%) for categorical variables. Categorical variables were analyzed by the chi-square test. Normally distributed variables were analyzed by the Student’s t test, while non-normally distributed variables were analyzed by Mann–Whitney test. Variables (Table 1 and infection sites) with P values of < 0.1 were included in Cox proportional hazards model to estimate hazard ratios (HRs) for AKI and mortality, and logistic regression model to estimate odds ratios (ORs) for clinical response. The effect of collinearity among variables (tolerance < 0.2 or variance inflation factor > 10) was eliminated in the models. Classification and regression tree (CART) method was used to split the samples into subgroups based on chi-square statistics. Thirty-day mortality and polymyxin B-associated AKI were compared with Kaplan–Meier analysis and log-rank test. P value of < 0.05 was considered significant.

Results

Patients Characteristics

A total of 486 patients received polymyxin B and had TDM during the study period. Ninety-three of them were excluded, and 393 patients were eventually included in the follow-up analysis (Fig. 1). The median age of the patients was 56 years old (IQR, 48–65 years), and
73.0% were male. Among them, 68 patients (17.3%) had multi-site infections. The highest infection site was lung (305/393), followed by bloodstream (96/393), abdomen (26/393), cerebral (17/393), urinary tract (11/393), and skin and soft tissue (6/393). Polymyxin-sensitive bacteria were observed in all patients with MICs $\leq 0.5$ mg/L.

Information on patient demographics, indications for therapy, and underlying conditions is presented in Table 1.

**Polymyxin B exposure and trough concentrations**

Observed and predicted polymyxin B concentrations from Bayesian estimation are shown in Fig. 2a. The coefficient of determination ($R^2$) of regression line was 0.997, which indicated the predictive performance of Bayesian approach. The median maintenance dose was 2.12 mg/kg/day (IQR, 1.67–2.50 mg/kg/day), which resulted in a median AUC$_{ss,24}$ h of 58.5 mg h/L (IQR, 40.6–77.2 mg h/L) and a median $C_{0h}$ of 1.24 mg/L (IQR, 0.74–1.93 mg/L). Figure 2b shows a positive correlation between $C_{0h}$ and AUC$_{ss,24}$ h with an $R^2$ of 0.793 was detected. Additionally, polymyxin B exposure increased with daily dosage, but it varied largely from patient to patient (Additional file 1: Figure S1).

**AKI**

AKI was observed in 29.0% of patients (114/393). Of these, 51 (44.7%) were classified as stage 1; 34 (29.8%) as stage 2; and 29 (25.4%) as stage 3. The median time to develop AKI was 8 days (IQR, 5–14 days). The median AUC$_{ss,24}$ h of AKI was significantly higher (78.2 mg h/L; IQR, 58.1–107.5 mg h/L) in patients who developed AKI than in those did not (50.6 mg h/L; IQR, 36.1–69.5 mg h/L; $P < 0.001$, Fig. 3a). As for AKI degrees (Additional file 1: Figure S2), AUC$_{ss,24}$ h of stage 3 was slightly higher than that of stage 1 ($P = 0.044$).

CART analysis (Fig. 4a) revealed that AUC$_{ss,24}$ h of $> 99.4$ mg h/L was significantly associated with

---

**Table 1** Patient characteristics

| Variable                        | All ($n = 393$) |
|---------------------------------|-----------------|
| Age, years                      | 56.0 (48.0–65.0)|
| Male, n (%)                     | 287 (73.0%)     |
| Weight, kg                      | 70.0 (60.0–75.0)|
| BMI, kg/m$^2$                   | 23.7 (21.2–25.7)|
| ICU admission, n (%)            | 361 (91.9%)     |
| Mechanical ventilation, n (%)   | 269 (68.4%)     |
| SOFA score                      | 8.0 (6.0–10.0)  |
| APACHE II score                 | 18.0 (13.0–23.0)|
| Comorbidities, n (%)            |                 |
| Diabetes                        | 127 (32.3%)     |
| Malignancy                      | 53 (13.5%)      |
| Hypertension                    | 162 (41.2%)     |
| Heart disease                   | 97 (24.7%)      |
| Stroke                          | 92 (23.4%)      |
| Sepsis                          | 186 (47.3%)     |
| Septic shock                    | 153 (38.9%)     |
| Pathogen, n (%)                 |                 |
| Klebsiella pneumoniae           | 177 (42.7%)     |
| Acinetobacter baumannii         | 168 (40.5%)     |
| Pseudomonas aeruginosa          | 44 (10.6%)      |
| Escherichia coli                | 17 (4.1%)       |
| Pneumogenic klebsiella          | 9 (2.2%)        |
| Polymyxin B treatment           |                 |
| Duration days                   | 13.0 (8.0–18.0) |
| Daily dose, mg                  | 150.0 (100.0–150.0) |
| Daily dose/weight, mg/kg/day    | 2.12 (1.67–2.50) |
| Concomitant antibiotics, n (%)  |                 |
| Carbapenem                      | 209 (53.2%)     |
| Cephalosporin                   | 184 (46.6%)     |
| Tigecycline                     | 136 (34.6%)     |
| Rifampicin                      | 25 (6.4%)       |
| Aminoglycosides                 | 12 (3.1%)       |
| Fosfomycin                      | 8 (2.0%)        |
| Aztreonam                       | 7 (1.8%)        |
| Laboratory data                 |                 |
| GFR, mL/min·1.73m$^2$           | 101.2 (71.3–118.3)|
| Scr, µmol/L                     | 62.0 (45.3–93.4)|
| Albumin, g/L                    | 30.0 (27.2–34.9)|
| White blood cell, 10$^9$/L      | 11.2 (8.0–15.7) |
| Platelets, 10$^9$/L             | 168.5 (88.0–275.3) |
| C-reactive protein, µg/L        | 72.2 (34.6–140.0) |
| Procalcitonin, ng/mL            | 1.0 (0.4–3.6)   |
| Concomitant nephrotoxic drugs, n (%) |            |
| Vancomycin                      | 83 (21.1%)      |
| Aminoglycoside                  | 12 (3.1%)       |
| Amphotericin B                  | 35 (8.9%)       |
| Furosemide                      | 154 (39.2%)     |
| Vasoactive drugs                | 195 (50.5%)     |
| Immunosuppressant               | 32 (8.1%)       |

**Table 1 (continued)**

| Variable                        | All ($n = 393$) |
|---------------------------------|-----------------|
| Use of nephrotoxic drugs$^a$    | 289 (73.5%)     |
| AUC$_{ss,24}$, mg h/L           | 58.5 (40.6–77.2)|
| $C_{0h}$, mg·L$^{-1}$           | 1.24 (0.74–1.93)|

Data were n (%) or median (interquartile range, IQR)

AKI: acute kidney injury; BMI: body mass index; ICU: intensive care unit; SOFA: Sequential Organ Failure Assessment; APACHE II: Acute Physiology, Age, Chronic Health Evaluation II; GFR: glomerular filtration rate; Scr: serum creatinine; AUC$_{ss,24}$ h: the area under the curve across 24 h at steady state; and $C_{0h}$: concentration pre-dose

$^a$ nephrotoxic drug including vancomycin, aminoglycoside, amphotericin B, furosemide, vasoactive drugs, and immunosuppressant
486 patients received polymyxin B and underwent therapeutic drug monitoring from Apr. 2018 to Mar. 2022

Exclude:
20 age < 18 years
53 received renal replacement therapy
14 had no pathogenic microorganism result
4 wrong blood drawing time
2 received polymyxin B treatment < 96 h

393 included in the analysis

114 had AKI
279 did not develop AKI

76 response/38 failed
63 survival/51 dead
173 response/106 failed
189 survival/88 dead

Fig. 1 Flow diagram of patient inclusion and exclusion. AKI, acute kidney injury

Fig. 2 Scatterplot of polymyxin B concentrations. Observed versus predicted polymyxin B concentration for Bayesian estimation approach (a). Bayesian estimated area under the curve across 24 h at steady state (AUC_{24h}) versus trough concentration (b)
AKI ($P < 0.001$). Then, subgroup analysis showed that patients with $\text{AUC}_{\text{ss},24\text{h}} > 49.1$ mg h/L had a higher risk of AKI than those with $\text{AUC}_{\text{ss},24\text{h}} \leq 49.1$ mg h/L ($P < 0.001$). These results were consistent with the target $\text{AUC}_{\text{ss},24\text{h}}$ window of 50–100 mg h/L [7], and accordingly, the following analysis took concentrations of 50 mg h/L and 100 mg h/L as cutoff points.

In both of Kaplan–Meier analysis (log-rank, $P < 0.001$, Fig. 5a) and Cox regression model (Table 2), AKI rate in $\text{AUC}_{\text{ss},24\text{h}} > 100$ mg h/L group (81.4%; HR 16.29, 95% CI 8.16–30.25, $P < 0.001$) was remarkably higher than that in $\text{AUC}_{\text{ss},24\text{h}}$ of 50–100 mg h/L group (32.8%; HR 3.89, 95% CI 2.17–6.97, $P < 0.001$) and $\text{AUC}_{\text{ss},24\text{h}}$ of < 50 mg h/L group (9.7%, $P < 0.001$).

In the case of $C_{0\text{h}}$, the median $C_{0\text{h}}$ was significantly higher (1.98 mg/L; IQR, 1.34–2.97 mg/L) in patients who developed AKI than in those did not (1.01 mg/L; IQR, 0.67–1.54 mg/L; $P < 0.001$, Fig. 3d). CART analysis (Fig. 4b) revealed that a cutoff value of 45.7 mg h/L split $\text{AUC}_{\text{ss},24\text{h}}$ levels into two nodes based on clinical response rate ($P < 0.001$), which was also in agreement with the lower limit of the target therapeutic window (50 mg h/L) [7, 9]. Logistic regression analysis (Table 3) showed that $\text{AUC}_{\text{ss},24\text{h}} \geq 50$ mg h/L (OR 4.39, 95% CI 2.56–7.47, $P < 0.001$) was an independent factor associated with clinical response, as were concomitant nephrotoxic drugs, age, and septic shock.
In addition, the median $C_{0\text{h}}$ was higher (1.35 mg/L; IQR, 0.85–2.09 mg/L) in patients with clinical response than with clinical failure (0.99 mg/L; IQR, 0.65–1.76 mg/L; $P < 0.001$, Fig. 3e), and maintenance of $C_{0\text{h}} > 1.01$ mg/L was identified to be correlated with clinical response (Fig. 4d).

Fig. 4 Classification and regression tree results for the incidence of AKI and clinical efficacy. $AUC_{\text{ss,24 h}}$ for AKI (a) and clinical efficacy (b); $C_{0\text{h}}$ for AKI (c) and clinical efficacy (d). AKI, acute kidney injury; $AUC_{\text{ss,24 h}}$, the area under the plasma concentration–time curve across 24 h at steady state; and $C_{0\text{h}}$, trough concentration

Fig. 5 Kaplan–Meier estimates of the incidence of AKI to day 30 after administration of polymyxin B. Stratified by $AUC_{\text{ss,24 h}}$ (a) and $C_{0\text{h}}$ (b). AKI, acute kidney injury; $AUC_{\text{ss,24 h}}$, the area under the plasma concentration–time curve across 24 h at steady state; and $C_{0\text{h}}$, trough concentration
Mortality
The 30-day all-cause mortality was 35.4% (139/393). No significant difference in AUC_{ss,24 h} between surviving and non-surviving patients was observed (58.3 mg h/L [39.5–75.2 mg h/L] vs. 58.2 mg h/L [43.1–83.4 mg h/L]; P = 0.184, Fig. 3c). And, there was no difference within each AUC_{ss,24 h} group with regard to 30-day mortality (34.2% vs. 34.9% vs. 41.9%, log-rank, P = 0.785, Additional

| Variable                  | No AKI (n = 279) | AKI (n = 114) | P* | HR (95% CI) | Pb |
|---------------------------|------------------|---------------|----|------------|----|
| Age, years                | 54.0 (47.0–64.0) | 58.0 (50.8–66.0) | 0.012 | 1.02 (1.01–1.03) | 0.003 |
| GFR, mL/min·1.73 m²       | 103.1 (74.0–121.3) | 95.5 (66.2–110.6) | 0.025 |
| Furosemide                | 101 (36.2%)      | 53 (46.5%)     | 0.058 |
| Use of nephrotoxic drugs  | 196 (70.3%)      | 93 (81.6%)     | 0.021 |

AUC_{ss,24 h} was derived from univariate analysis (P < 0.05).

AUC_{ss,24 h} was derived from Cox regression analysis (P < 0.05).

C0h was not included in the logistic regression model due to collinearity with AUC_{ss,24 h}.

| Variable                  | Failure (n = 144) | Response (n = 249) | P* | OR (95% CI) | Pb |
|---------------------------|------------------|-------------------|----|------------|----|
| Age, years                | 58.0 (51.0–67.0) | 54.0 (47.0–63.0) | 0.009 | 0.98 (0.96–1.0) | 0.012 |
| SOFA score                | 8.0 (7.0–12.0)   | 8.0 (5.0–10.0)    | 0.003 |
| APACHE II score           | 19.0 (14.0–23.0) | 17.0 (11.0–21.0) | 0.001 |
| Septic shock              | 69 (47.6%)       | 84 (33.9%)       | 0.007 | 0.55 (0.33–0.93) | 0.025 |
| Vasoactive drugs          | 87 (60.8%)       | 108 (44.4%)      | 0.002 |
| Use of nephrotoxic drugs  | 117 (80.7%)      | 172 (69.4%)      | 0.014 | 0.44 (0.24–0.83) | 0.011 |
| Laboratory data           |                  |                   |    |            |    |
| GFR, mL/min·1.73 m²       | 96.0 (51.8–114.4) | 102.7 (73.7–118.0) | 0.049 |
| Albumin, g/L              | 29.2 (26.2–33.2) | 30.5 (27.3–35.0) | 0.080 |
| Platelets, 10^9/L         | 139.0 (73.0–244.0) | 172.5 (85.5–271.0) | 0.008 |
| C-reactive protein, μg/L  | 89.4 (45.9–150.0) | 67.6 (30.8–130.7) | 0.072 |
| Procalcitonin, ng/mL      | 1.2 (0.5–4.0)    | 0.9 (0.3–3.5)    | 0.080 |

AUC_{ss,24 h} was derived from logistic regression analysis (P < 0.05).

C0h was not included in the logistic regression model due to collinearity with AUC_{ss,24 h}.

OR odds ratio; CI confidence interval; GFR glomerular filtration rate; and AUC_{ss,24 h} the area under the curve across 24 h at steady state.
In the previous study, we found that an AUC_{ss,24h} of > 100 mg h/L was a good predictor for the probability of nephrotoxicity by both the receiver operating characteristic curve and logistic regression analysis [16]. Unable to estimate AUC, Han et al. reported that C_{oh} > 3.13 mg/L significantly increased the risk of AKI [18]. According to the limited sampling strategy equation (AUC_{ss,24h} = 21.323 + 28.189 \times C_{oh}) [29], the C_{oh} value (3.13 mg/L) was equivalent to an AUC_{ss,24h} of 109.6 mg h/L. These results also supported the rationality of the upper bound of AUC_{ss,24h} (100 mg h/L).

For antibiotics with AUC/MIC as PK/PD index, AUC better predicts efficacy and toxicity but is more challenging to get in clinical practice than C_{oh} [30, 31]. Several approaches have been proposed to estimate AUC with sparse samples, such as Bayesian method, limited sampling strategy, and Sawchuk–Zaske equation [26, 29, 32]. Using Bayesian approach, we found that C_{oh} had an apparent relationship with AUC (Fig. 2b). Moreover, CART analysis identified two cutoff points of 1.23 mg/L and 2.75 mg/L as significant predictors of the incidence of AKI (Fig. 4c) and C_{oh} of > 1.01 mg/L as a predictor for clinical response (Fig. 4d). Based on these results, we developed a model that correlates AUC_{ss,24h} and C_{oh}.

### Discussion

This study investigated and evaluated the association between an AUC_{ss,24h} threshold and polymyxin B exposure–response/toxicity using clinical data from critically ill patients with CR-CNB infections. As a result, a significant relationship between polymyxin B AUC_{ss,24h} and clinical efficacy/AKI was observed. CART analysis identified two cutoff points of 99.4 mg h/L and 49.1 mg h/L as significant predictors of the incidence of AKI, and AUC_{ss,24h} of > 45.7 mg h/L was significantly associated with clinical response (Fig. 4). These results were in accordance with the therapeutic window (50–100 mg h/L) and were also validated by regression analyses and Kaplan–Meier analysis in this study.

### Table 4: Univariate and Cox regression model for 30-day mortality

| Variable                               | Survival (n = 254) | No survival (n = 139) | P<sup>a</sup> | HR (95% CI) | P<sup>b</sup> |
|----------------------------------------|--------------------|-----------------------|---------------|-------------|---------------|
| Age, years                             | 54.0 (48.0–63.0)   | 59.0 (48.0–68.0)      | <0.001        | 1.92 (1.31–2.83) | 0.001         |
| ICU admission, n (%)                    | 229 (90.2%)        | 132 (95.0%)           | 0.096         |             |               |
| Mechanical ventilation                 | 163 (64.2%)        | 106 (76.3%)           | 0.014         | 0.99 (0.99–1.0) | 0.001         |
| SOFA score                             | 8.0 (5.0–10.0)     | 9.0 (7.0–12.0)        | <0.001        | 2.29 (1.54–3.40) | <0.001         |
| APACHE II score                        | 17.0 (11.0–21.8)   | 19.0 (14.0–24.0)      | 0.002         |             |               |
| Comorbidities                          |                    |                       |               |             |               |
| Diabetes                               | 74 (29.1%)         | 53 (38.1%)            | 0.068         |             |               |
| Heart disease                          | 46 (18.1%)         | 51 (36.7%)            | <0.001        | 1.92 (1.31–2.83) | 0.001         |
| Sepsis                                 | 106 (41.7%)        | 80 (57.6%)            | 0.003         |             |               |
| Septic shock                           | 75 (29.5%)         | 78 (56.1%)            | <0.001        | 2.29 (1.54–3.40) | <0.001         |
| Laboratory data                        |                    |                       |               |             |               |
| GFR, mL/min·1.73m<sup>2</sup>          | 103.1 (80.6–118.9) | 86.5 (41.8–110.9)     | <0.001        | 0.99 (0.99–1.0) | 0.001         |
| Albumin, g/L                           | 30.2 (27.3–34.9)   | 29.2 (26.6–32.9)      | 0.021         |             |               |
| Platelets, 10<sup>9</sup>/L            | 178.0 (84.3–294.8) | 127.0 (71.0–194.0)    | <0.001        |             |               |
| C-reactive protein, μg/L               | 68.1 (30.4–127.2)  | 107.5 (47.3–159.9)    | 0.001         |             |               |
| Procalcitonin, ng/mL                   | 0.7 (0.3–3.4)      | 1.4 (0.6–5.9)         | <0.001        |             |               |
| Concomitant nephrotoxic drugs          |                    |                       |               |             |               |
| Vancomycin                             | 43 (16.9%)         | 40 (28.8%)            | 0.006         |             |               |
| Furosemide                             | 89 (35.0%)         | 65 (47.1%)            | 0.020         |             |               |
| Vasoactive drugs                       | 110 (43.8%)        | 85 (63.0%)            | <0.001        |             |               |
| Use of nephrotoxic drugs               | 166 (65.4%)        | 123 (88.5%)           | <0.001        | 2.70 (1.48–4.93) | 0.001         |
| AKI                                    | 63 (24.8%)         | 51 (36.7%)            | 0.013         |             |               |

<sup>a</sup> derived from univariate analysis
<sup>b</sup> derived from Cox regression analysis

HR: hazard ratio; CI: confidence interval; and GFR: glomerular filtration rate
on the regression equation (Fig. 2b), these $C_{0h}$ values (1.23 mg/L, 2.75 mg/L, and 1.01 mg/L) were, respectively, equivalent to AUC$_{ss, 24\text{h}}$ of 55.1 mg h/L, 100.9 mg h/L, and 49.6 mg h/L, which were close to the AUC target. Since the incidence of AKI was very low when $C_{0h} \leq 1.23$ mg/L (8.7%), to avoid the emergence of drug-resistant bacteria caused by low drug exposure, $C_{0h}$ therapeutic target was simplified to 1.2–2.8 mg/L. Alternatively, in the absence of methods to calculate AUC, $C_{0h}$ would be a credible surrogate for dosing adjustment.

Besides drug exposures, older age was also associated with polymyxin B-related AKI in Cox regression model (Table 2). Meta-analyses showed the primary factor affecting nephrotoxicity was polymyxins B dose, along with age, diabetes, and use of nephrotoxins [12, 13, 33]. Most of the above risk factors were found in the univariate analysis but had no effect in Cox regression model. This disparity was attributable to the fact that polymyxin B dose was associated with AUC$_{ss, 24\text{h}}$ which showed a more remarkable impact on nephrotoxicity. Therefore, TDM is recommended to decrease the risk of nephrotoxicity.

Compared with AKI, polymyxin B exposures had less effect on clinical response and had no effect on 30-day mortality (Fig. 3). It was also found in the vancomycin exposure–response relationship studies [34–36]. Since this was a retrospective study, these data should be interpreted cautiously. The main reason might be that AUC/MIC ratio, not AUC, was the PK/PD parameter most closely linked to clinical outcomes [4]. In this study, polymyxin-sensitive bacteria were observed in all patients with MICs $\leq 0.5$ mg/L by a VITEK$^\text{®}$ 2 COMPACT automated system rather than broth microdilution (BMD) testing. Nevertheless, Zhu et al. observed that the MICs of polymyxin in several susceptible isolates tested by the VITEK 2 system were onefold to twofold dilutions lower than those of BMD [37]. This may be the reason why the guideline recommends the use of BMD assays to assess the MICs of polymyxins [7]. Additionally, critically ill patients suffered serious underlying diseases and comorbidities, mixed infection, and a combination of multiple drugs, which also affected the eventual efficacy of polymyxin B and mortality.

This study has several limitations to be considered. First, this was a single-center retrospective study of adult, non-dialysis patients. It is unknown whether the observed findings apply to other populations. Second, the AUC threshold was delineated by CART, a useful tool to identify exposure thresholds associated with an increased risk of outcomes. Although it recognized the breakpoint that maximizes the difference in outcomes in a given study sample, it should be validated with external data. Third, this population was identified over 4 years, so unmeasured changes in CR-GNB management may result in improved outcomes over time. Known changes over this period include changes in polymyxin B dosing in accordance with consensus guidelines [7] and novel co-administered agents such as ceftazidime–avibactam [38]. Last, to truly define the polymyxin B exposure–efficacy relationship, large-scale, multicentered prospective clinical trials are needed with the AUC/MIC analysis, which is under preparation at our center.

**Conclusions**

In conclusion, the present study confirmed a significant relationship between polymyxin B AUC$_{ss, 24\text{h}}$ and clinical efficacy/AKI in a real-world cohort of patients treated with polymyxin B for CR-GNB infections. AUC$_{ss, 24\text{h}}$ threshold of 50–100 mg h/L was a good predictor for clinical response and AKI risk, and $C_{0h}$ (1.2–2.8 mg/L) monitoring was also a credible surrogate for individualized dosing. Accordingly, it is necessary to recommend TDM and AUC-guided polymyxin B dosing.

**Abbreviations**

CR-GNB: Carbapenem-resistant gram-negative bacteria; AKI: Acute kidney injury; PK: Pharmacokinetics; PD: Pharmacodynamics; TD: Toxicodynamic; TDM: Therapeutic drug monitoring; AUC$_{ss, 24\text{h}}$: Area under the concentration–time curve across 24 h at steady state; MIC: Minimum inhibitory concentration; $C_{0h}$ or $C_{min}$: Trough concentration; EUCAST: European Committee on Antimicrobial Susceptibility Testing; APACHE II: Acute Physiology and Chronic Health Enquiry; SOFA: Sequential Organ Failure Assessment; C2h: Concentration after 2 h dose; CrCL: Creatinine clearance; KDIGO: Kidney Disease Improving Global Outcomes; IQR: Interquartile range; HR: Hazard ratio; OR: Odds ratios; CART: Classification and regression tree; R$^2$: Coefficient of determination; BMD: Broth microdilution.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13054-022-04195-7.

**Additional file 1: Figure S1.** Scatterplot of polymyxin B AUC$_{ss, 24\text{h}}$ versus dosage. AUC$_{ss, 24\text{h}}$, the area under the plasma concentration-time curve across 24 hours at steady state. **Figure S2.** Scatterplot of polymyxin B AUC$_{ss, 24\text{h}}$ (a) and $C_{0h}$ (b) stratified for different stages of acute kidney injury. AUC$_{ss, 24\text{h}}$, the area under the plasma concentration-time curve across 24 hours at steady state; $C_{0h}$, trough concentration. **Figure S3.** Kaplan-Meier estimates of survival to 30 days after administration of polymyxin B. Stratified by AUC$_{ss, 24\text{h}}$ (a) and $C_{0h}$ (b), AUC$_{ss, 24\text{h}}$, the area under the plasma concentration-time curve across 24 hours at steady state; $C_{0h}$, trough concentration.

**Author contributions**

JY, PW, and SL contributed to data acquisition, analysis, and interpretation. JY contributed to manuscript preparation. JL performed the experiments. PW supervised the research and revised the manuscript. TS and XZ designed the research. All authors approved the final manuscript.

**Funding**

This work was supported by the National Key R&D Program of China (Grant No. 2020YFC2008304).
Availability of data and materials
The datasets used during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
This study was approved by the Ethics Committees of the First Affiliated Hospital of Zhengzhou University (2020-KY-0318) and waived informed consent.

Consent for publication
All authors have consented to the publication of the present manuscript.

Competing interests
The authors declare that they have no conflicts of interest.

Author details
1. Department of Pharmacy, First Affiliated Hospital of Zhengzhou University, No. 1 Jianhe East Road, Zhengzhou, Henan 45005, People’s Republic of China. 2. Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou, People’s Republic of China. 3. Henan Engineering Research Center for Application and Translation of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou, People’s Republic of China. 4. Department of General Intensive Care Unit, First Affiliated Hospital of Zhengzhou University, Zhengzhou, People’s Republic of China.

Received: 9 August 2022  Accepted: 11 October 2022

Published online: 18 October 2022

References
1. Velkov T, Roberts KD, Nation RL, Thompson PE, Li J. Pharmacology of polymyxins: new insights into an old class of antibiotics. Future Microbiol. 2013;8(6):711–24.
2. Paul M, Carrara E, Retamar P, Tängdén T, Bitterman R, Bonomo RA, et al. European society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect. 2022;28(4):S21–47.
3. Rigatto NH, Oliveira MS, Perdigão-Neto LV, Levin AS, Carrilho CM, Tanita MT, et al. Multicenter prospective cohort study of renal failure in patients treated with colistin versus polymyxin B. Antimicrob Agents Ch. 2016;60(4):2445–9.
4. Tängdén T, Ramos Martín V, Felton T, Nielsen EL, Marchand S, Brüggemann RJ, et al. The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections. Intensive Care Med. 2017;43(7):1021–32.
5. Sandri AM, Landersdorfer CB, Jacob J, Bonatti MM, Dalarosa MG, Falcí DR, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis. 2013;57(4):524–31.
6. Tran TB, Velkov T, Nation RL, Forrest A, Tsuji BT, Bergen PJ, et al. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: Are we there yet? Int J Antimicrob Agents. 2016;48(6):592–7.
7. Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP), European society of clinical microbiology and infectious diseases (ESCMID), infectious diseases society of America (IDSA) international society for anti-infective pharmacology (ISAP), society of critical care medicine (SCCM), and society of infectious diseases pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10–39.
8. Satlin MJ, Lewis JS, Weinstein MP, Jean P, Humphries RM, Gunnar K, et al. Clinical and laboratory standards institute and European committee on antimicrobial susceptibility testing position statements on polymyxin B and colistin clinical breakpoints. Clin Infecc Dis. 2020;70(19):S523–9.
9. Lakota EA, Landersdorfer CB, Nation RL, Li J, Kaye KS, Rao GG, et al. Personalizing polymyxin B dosing using an adaptive feedback control algorithm. Antimicrob Agents Ch. 2018;62(7):e00483-e418.
10. Alonsoy S, Jorgensen SC, Rybak MJ. The optimal use of the polymyxins before their time is up. Pharmacotherapy. 2019;39(1):7–9.
11. Tuon FF, Rigatto MH, Lopes CK, Kamei LR, Rocha JL, Zavascki AP. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Ag. 2014;43(4):345–52.
12. Wagenlehner F, Lucentefort E, Pea F, Soriano A, Tavoschi L, Steele VR, et al. Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins. Clin Microbiol Infect. 2021;27(S):671–86.
13. Sisay M, Hagos B, Edessa D, Tadivosy Y, Merukia AN. Polymyxin-induced nephrotoxicity and its predictors: a systematic review and meta-analysis of studies conducted using RIFLE criteria of acute kidney injury. Pharmacol Res. 2021;163: 105328.
14. Yang XJ, Qi SY, Duan XS, Han B, Zhang SG, Liu SH, et al. Clinical outcomes and safety of polymyxin B in the treatment of carbapenem-resistant gram-negative bacterial infections: a real-world multicenter study. J Transl Med. 2021;19:431.
15. Chen N, Guo J, Xie J, Xu M, Hao X, Ma K, et al. Population pharmacokinetics of polymyxin B: a systematic review. Ann Transl Med. 2022;10(4):231.
16. Wang PL, Zhang QW, Zhu ZF, Pei H, Feng M, Sun TW, et al. Comparing population pharmacokinetics and acute kidney injury of polymyxin B in Chinese patients with and without renal insufficiency. Antimicrob Agents Ch. 2021;62(20):e01900-01920.
17. Ye Q, Wang Q, Chen Z, Han W, Zhan Q, Wang C. Effectiveness, nephrotoxicity, and therapeutic drug monitoring of polymyxin B in nosocomial pneumonia among critically ill patients. Clin Resp J. 2022;16(5):402–12.
18. Han L, Xu FM, Zhang XS, Zhang CH, Dai Y, Zhou ZY, et al. Trough polymyxin B plasma concentrations is an independent risk factor for its nephrotoxicity. Br J Clin Pharmacol. 2022;88(3):1202–10.
19. Cheng Y, Gu JY, Li X, Tong H, Guo SW, Xu B, et al. Does monitoring total and free polymyxin B plasma concentrations predict polymyxin B-induced nephrotoxicity? A retrospective study in critically ill patients. Infect Dis Ther. 2022;11(4):1591–608.
20. Abdul-Azziz MH, Affenaar JWC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med. 2020;46(6):1127–23.
21. EUCAST. European Committee on antimicrobial susceptibility testing breakpoint tables for interpretation of MICs and zone diameters. Version 7.1. In: 2017.
22. Larvin M, Mcmahon MJ. APACHE-II score for assessment and monitoring of acute pancreatitis. Lancet. 1989;334(8656):201–5.
23. Vincent JL, De Mendonça A, Cantraine F, Moreno A, Takala J, Suter PM, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care unit results of a multicenter, prospective study. Crit Care Med. 1998;26(11):1793–800.
24. Guan X, He L, Hu B, Hu J, Huang X, Lai G, et al. Laboratory diagnosis, clinical management and infection control of the infections caused by extensively drug-resistant gram-negative bacilli: a Chinese consensus statement. Clin Microbiol Infect. 2016;22:515–25.
25. Wang PL, Zhang QW, Qin ZF, Xing H, Xu M, Pei H, et al. A simple and robust LC-MS/MS analytical method for therapeutic drug monitoring of plasma and cerebrospinal fluid polymyxin B1 and B2. Ther Drug Monit. 2020;42:716–23.
26. Wang PL, Zhang QW, Zhu ZF, Feng M, Sun TW, Yang J, et al. Population pharmacokinetics and limited sampling strategy for therapeutic drug monitoring of polymyxin B in Chinese patients with multidrug-resistant Gram-negative bacterial infections: Front Pharmacol. 2020;11:829.
27. Levey AS, Coresh J, Bolton K, Cullerton B, Harvey KS, Ikizler TA, et al. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 SUPPL. 1):S1-S266.
28. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179-184.
29. Chen W, Liu H, Wang Q, Wang X, Kong X, Wang X, et al. Estimation of the area under concentration-time curve of polymyxin B based on limited sampling concentrations in Chinese patients with severe pneumonia. Eur J Pharm Sci. 2021;77:95–105.
30. Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American society of health-system pharmacists, the infectious diseases society of America (ISAP), society of critical care medicine (SCCM), and society of infectious diseases pharmacists (SIDP). J Pharm Sci. 2021;77:95–105.
society of America, the pediatric infectious diseases society, and the society of infectious diseases pharmacists. Clin Infect Dis. 2020;71(6):1361–4.
31. Wicha SG, Mårtson AG, Nielsen EI, Koch BC, Friberg LE, Alffenaar JW, et al. From therapeutic drug monitoring to model-informed precision dosing for antibiotics. Clin Pharmacol Ther. 2021;109(4):928–41.
32. Pai MP, Neely M, Rodvold KA, Lodise TP. Innovative approaches to optimizing the delivery of vancomycin in individual patients. Adv Drug Deliv Rev. 2014;77:50–7.
33. Rigatto MH, Behle TF, Falci DR, Freitas T, Lopes NT, Nunes M, et al. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study. J Antimicrob Chemother. 2015;70(5):1552–7.
34. Ueda T, Takesue Y, Nakajima K, Ichiki K, Ishikawa K, Yamada K, et al. Validation of vancomycin area under the concentration-time curve estimation by the Bayesian approach using one-point samples for predicting clinical outcomes in patients with methicillin-resistant Staphylococcus aureus infections. Antibiotics. 2022;11:96.
35. Dalton B, Rajakumar I, Langevin A, Ondro C, Sabuda D, Griener T, et al. Vancomycin area under the curve to minimum inhibitory concentration ratio predicting clinical outcome: a systematic review and meta-analysis with pooled sensitivity and specificity. Clin Microbiol Infect. 2020;26(4):436–46.
36. Dilworth TJ, Schulz LT, Rose WE. Vancomycin advanced therapeutic drug monitoring: Exercise in futility or virtuous endeavor to improve drug efficacy and safety? Clin Infec Dis. 2021;72(10):e675–81.
37. Zhu Y, Jia P, Zhou M, Zhang J, Zhang G, Kang W, et al. Evaluation of the clinical systems for polymyxin susceptibility testing of clinical Gram-negative bacteria in China. Front Microbiol. 2021;11:610604.
38. Doi Y. Treatment options for carbapenem-resistant gram-negative bacterial infections. Clin Infec Dis. 2019;69(Supplement_7):S565–75. https://doi.org/10.1093/cid/ciz830.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.